+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

O

Actively Recruiting

This observational study follows patients with relapsing multiple sclerosis RMS who are being treated with approved injectable or selected oral disease-modifying therapies DMTs in Germany. The study is non-interventional and open-label, designed to collect real-world data on treatment and disease progression over several years. It aims to understand how patients continue their baseline treatments and how these treatments impact various health and quality of life measures. Participants receive routine medical care with approved injectable or oral DMTs such as ofatumumab, interferon b21, glatiramer acetate, teriflunomide, dimethyl fumarate, or diroximel fumarate. The study includes two cohorts with up to approximately two years of prospective observation each, with an optional extension allowing up to four years total. Treatment decisions and monitoring follow the patients usual care and physicians discretion, including routine visits and telemedicine options. During the study, participants provide medical history, complete questionnaires, and have data collected on disability status, MRI findings, relapses, and laboratory tests. Researchers assess treatment continuation rates, fatigue, anxiety, depression, quality of life, lesion counts, and relapse rates at multiple time points. Safety and treatment interruptions are also documented. Follow-up is flexible and based on standard care procedures, with data collection occurring throughout the observational periods.

Age: 18Years - 100YearsAll Genders
141 locations
G

Actively Recruiting

Researchers are evaluating the effectiveness and safety of combining Dato-DXd with rilvegostomig as an additional treatment compared to standard care in adults with high-risk muscle invasive urothelial carcinoma MIUC who have undergone radical surgery. This Phase III trial focuses on participants with residual disease at high risk of recurrence after surgery. The study aims to see if the new combination improves disease-free survival compared to current standard treatments. Participants are randomly assigned to one of three groups Arm 1 receives Dato-DXd plus rilvegostomig intravenously every three weeks for up to one year Arm 2 receives Dato-DXd alone on the same schedule Arm 3 receives standard care, which includes nivolumab, durvalumab, or a combination of enfortumab vedotin and pembrolizumab, given intravenously at intervals ranging from every two to four weeks for up to a year. Treatment duration and dosing can be adjusted based on tolerance and investigator assessment. During the trial, participants will have visits approximately every three weeks or as per standard care schedules, depending on their assigned group, for up to 12 months of treatment. Researchers will monitor disease recurrence and survival outcomes for up to 78 months from the first participants enrollment. Assessments include clinical evaluations and disease status monitoring to measure disease-free survival and overall survival. Participants will be followed closely to assess safety and effectiveness of the treatments over this extended period.

Age: 18Years +All GendersPhase 3
160 locations
A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of intravesical administration of detalimogene EG-70, a novel non-viral gene therapy, in patients with non-muscle invasive bladder cancer NMIBC. The study focuses on patients with carcinoma in situ CIS unresponsive to BCG therapy and other high-risk NMIBC patients, including those who are BCG-nafve or incompletely treated. The trial includes a Phase 1 dose-escalation to determine safety and recommended dose, followed by a Phase 2 to assess treatment effectiveness. Participants will receive EG-70 via bladder instillation with a catheter in cycles lasting about 12 weeks. Phase 1 involves up to four cycles with either two or four doses per cycle, aiming for a 60-minute retention time. Phase 2 participants receive four instillations per cycle for up to four cycles at the recommended dose. Those achieving complete response may continue with maintenance treatment involving two doses per 12-week cycle. A substudy includes a surfactant bladder rinse before EG-70 instillation, with a shortened administration time. During the study, participants undergo regular assessments including cystoscopy, urine cytology, and biopsies to monitor response and safety. Researchers track adverse events, treatment response rates, duration of response, progression-free survival, and quality of life over periods ranging from weeks to years. Safety monitoring follows standardized criteria, and participants may continue in maintenance cycles if responding. The total study duration extends up to approximately nine years from start to completion.

Age: 18Years +All GendersPhase 1Phase 2
102 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness of saruparib combined with a physicians choice of androgen receptor pathway inhibitors ARPI compared with a placebo plus ARPI in men who have metastatic hormone-sensitive prostate cancer mHSPC. These men have previously been treated with docetaxel chemotherapy or PSMA-directed lutetium-177 radioligand therapy and show no signs of disease progression, with PSA levels equal to or above 0.2 ngmL. This phase III randomized study aims to measure the impact of these treatments on disease progression. Participants receive either saruparib 60 mg orally once daily along with a chosen ARPI enzalutamide, darolutamide, or abiraterone in 28-day cycles or a placebo plus the same ARPI regimen in similar cycles. The study is double-blind and includes two cohorts, comparing the combined use of saruparib and ARPI against placebo and ARPI. Treatment continues under medical supervision with regular monitoring. During the study, participants undergo evaluations to measure radiographic progression-free survival up to approximately 56 months, along with other outcomes such as overall survival, time to progression, symptomatic skeletal events, PSA progression, and physical function changes. Blood samples and tumor tissue are collected for biomarker analysis. Safety and treatment effects are closely monitored throughout the study, which may last several years.

Age: 18Years +MALEPhase 3
210 locations
R

Actively Recruiting

Researchers are evaluating whether combining the investigational drug mevrometostat PF-06821497 with enzalutamide works better than enzalutamide alone in men with metastatic castration-sensitive prostate cancer mCSPC who have not received androgen receptor pathway inhibitors or chemotherapy for mCSPC. This Phase 3, global, multicenter, randomized, double-blind, placebo-controlled study focuses on participants with prior limited androgen-deprivation therapy and no disease progression or rising PSA before treatment starts. Participants are randomly assigned to one of two groups one receives mevrometostat 875 mg twice daily plus enzalutamide 160 mg once daily, and the other receives a placebo plus enzalutamide at the same dose. The study includes a screening phase, treatment phase, safety follow-up, and long-term follow-up. Treatment is oral and taken continuously during the trial. During the study, participants undergo various assessments including imaging scans to track disease progression, laboratory tests, and patient-reported questionnaires on pain, quality of life, and fatigue. Researchers will monitor radiographic progression-free survival for up to about 4 years and overall survival for up to about 9 years. Safety and pharmacokinetics of mevrometostat combined with enzalutamide are also evaluated. The total duration includes screening, treatment, safety monitoring, and extended follow-up phases.

Age: 18Years +MALEPhase 3
319 locations